 2021 Earnings Call Summary

Labcorp reported strong results in the third quarter, with revenue totaling $4.1 billion, adjusted earnings per share reaching $6.82, and free cash flow of $650 million. The company's Diagnostics and Drug Development businesses performed well, with 10% and 22% growth, respectively. COVID testing volumes were higher than anticipated, but the time to results for COVID tests remained an average of one to two days. Labcorp continues to support the fight against the pandemic through both its diagnostic and drug development capabilities. The company has received emergency use authorization for a COVID and flu-at-home collection kit, and is collaborating with AstraZeneca on both a COVID prevention and treatment trial. Labcorp is also working on bringing new innovations to market, including a combined COVID and flu-at-home collection kit. The company is raising full-year guidance for revenue, adjusted earnings per share, and free cash flow, with expectations for strong growth in all segments.